Comparison of the 2025 ESC/EAS and 2026 ACC/AHA Guidelines for Dyslipidemia Management

Area of Science:

• Cardiology
• Preventive Medicine
• Lipid Metabolism

Background:

• Recent updates to European (ESC/EAS) and American (ACC/AHA) dyslipidemia guidelines signify a paradigm shift in preventive cardiology.
• Both guidelines acknowledge low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins as causal factors in atherosclerotic cardiovascular disease (ASCVD).

Purpose of the Study:

• To compare and contrast the 2025 ESC/EAS and 2026 ACC/AHA dyslipidemia guidelines.
• To highlight differences in clinical practice organization, risk assessment, and treatment strategies.
• To identify areas of convergence in contemporary lipid management.

Main Methods:

• Comparative analysis of the 2025 ESC/EAS and 2026 ACC/AHA dyslipidemia guidelines.
• Examination of differences in risk stratification, treatment goals, and therapeutic escalation.
• Evaluation of the incorporation of biomarkers, imaging, and shared decision-making.

Main Results:

• The European framework emphasizes explicit risk categories, LDL-C goals, and treatment escalation.
• The American framework prioritizes lifetime risk, coronary artery calcium, non-HDL-C, apolipoprotein B, lipoprotein(a), and shared decision-making.
• Differences impact patient classification, treatment intensity, and use of non-statin therapies, especially in primary prevention and subclinical atherosclerosis.

Conclusions:

• Both guidelines advocate for earlier, deeper, and sustained reduction of atherogenic lipoproteins.
• There is a convergence on reduced tolerance for prolonged lipoprotein exposure and broader use of combination lipid-lowering therapy.
• Selective use of biomarkers and imaging refines prevention strategies, offering complementary models for lipid management.